Ongoing 5-year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer

BACKGROUND: Advancements in chemotherapy for metastatic colorectal cancer (mCRC) have improved long-term outcomes, and median survival currently exceeds 30 months. The recommended treatment for mCRC is multidisciplinary, including a combination of surgical resection and chemotherapy. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuishi, Kozue, Miyamoto, Yuji, Hiyoshi, Yukiharu, Tokunaga, Ryuma, Imai, Katsunori, Hayashi, Hiromitsu, Yamashita, Yoichi, Yoshida, Naoya, Baba, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316900/
https://www.ncbi.nlm.nih.gov/pubmed/32588352
http://dx.doi.org/10.1186/s40792-020-00913-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316900/
https://www.ncbi.nlm.nih.gov/pubmed/32588352
http://dx.doi.org/10.1186/s40792-020-00913-x

Ejemplares similares